Related Experiment Video
Updated: Apr 5, 2026

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
Published on: May 8, 2017
Bedaquiline and delamanid in tuberculosis
Susanna Esposito1, Sonia Bianchini1, Francesco Blasi2
1a 1 Università degli Studi di Milano, Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan, Italy +39 02 55 03 24 98 ; +39 02 50 32 02 06 ; susanna.esposito@unimi.it.
New drugs bedaquiline and delamanid show promise for treating drug-resistant tuberculosis (TB). While effective in adults, further pediatric studies are needed to assess safety and drug interactions.
Area of Science:
- Pharmacology and Infectious Diseases
- Tuberculosis Treatment and Drug Development
Background:
- Rising emergence of drug-resistant tuberculosis (TB) necessitates novel therapeutic agents.
- Factors contributing to resistance include poor adherence, drug quality, and treatment errors.
Purpose of the Study:
- To review the characteristics and role of bedaquiline and delamanid in managing resistant TB.
- To evaluate the efficacy and safety profiles of these new anti-TB drugs.
Main Methods:
- Review of existing literature on bedaquiline and delamanid.
- Summary of pharmacological properties, efficacy, and safety data.
Main Results:
- Bedaquiline and delamanid demonstrate promising efficacy against resistant pulmonary TB in adults.
- These drugs possess unique mechanisms of action, distinct from older anti-TB agents.
- Potential cardiologic side effects, such as QT-interval prolongation, require monitoring.
Conclusions:
- Bedaquiline and delamanid represent significant advancements in treating resistant TB.
- Further pediatric studies are crucial to confirm efficacy and safety in younger populations.
- Consideration of drug interactions is vital due to the long treatment duration for resistant TB.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Anthelminthic Agents

